Unraveling the structural basis of grazoprevir potency against clinically relevant substitutions in hepatitis C virus NS3/4A protease from genotype 1a

Grazoprevir is a potent pan-genotype and macrocyclic inhibitor of hepatitis C virus (HCV) NS3/4A protease and was developed for treating chronic HCV infection. In HCV genotype (GT) 1a, grazoprevir maintains potent activity against a majority of NS3 resistance-associated amino acid substitutions, inc...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Biol Chem
Autors principals: Guo, Zhuyan, Black, Stuart, Hu, Yuan, McMonagle, Patricia, Ingravallo, Paul, Chase, Robert, Curry, Stephanie, Asante-Appiah, Ernest
Format: Artigo
Idioma:Inglês
Publicat: American Society for Biochemistry and Molecular Biology 2017
Matèries:
Computational Biology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5391751/
https://ncbi.nlm.nih.gov/pubmed/28228479
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1074/jbc.M116.772996
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars